Analytical Data
-
Gene name
Bcl6B
- Application
-
Alternative Names
BAZF; ZBTB28; ZNF62; Zinc Finger Protein 62; Bcl6-associated zinc finger protein
-
Species
Mouse
-
Source
E. coli
-
Tag
N- His & GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O88282
-
Expression Region
Gly139~Pro474
-
Molecular Weight
71kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Bcl6B, part of the Bcl-6 gene family, has garnered significant attention in recent years due to its critical role in immune regulation and potential implications in various diseases, including cancers and autoimmune disorders. Initially identified as a transcriptional repressor involved in B-cell development, Bcl6B exhibits unique expression patterns that suggest a broader physiological functionality. Research indicates that Bcl6B can influence the differentiation of T-helper cells, particularly in modulating Th17 and regulatory T cell populations, thereby affecting inflammatory responses. The protein's ability to intervene in the transcriptional networks governing immune responses makes it a focal point for therapeutic exploration. Beyond its immune functions, recent studies have revealed that Bcl6B may engage in tumorigenesis through the modulation of oncogenic pathways, highlighting its relevance in cancer biology. Consequently, recombinant Bcl6B protein has become a valuable tool for researchers aiming to unravel its mechanistic roles and therapeutic potential. Understanding Bcl6B’s multifaceted activities could pave the way for innovative strategies in treating immune-related diseases and cancers, establishing it as a promising candidate for future drug development.
